Amgen agreed to acquire Dark Blue Therapeutics for up to $840 million to add a preclinical small-molecule degrader targeting MLLT1/3 and related programs aimed at acute myeloid leukemia (AML). Amgen said the asset demonstrated preclinical anti-cancer activity and mechanistic differentiation from existing therapies. Amgen’s R&D chief framed the acquisition as strategic for its targeted protein degradation efforts and leukemia portfolio. Dark Blue’s discovery work, spun out of Oxford University, will be integrated into Amgen’s oncology pipeline; companies said the deal expands Amgen’s early‑stage precision oncology footprint.